Suppression of androgen receptor (AR) activity in prostate malignancy by androgen depletion or direct AR antagonist treatment, although initially effective, potential clients to incurable castration resistant prostate tumor (CRPC) via compensatory systems including resurgence of AR and AR splice version (ARV) signaling. degradation of AR and ARV, suppressing the transcriptional activity and proteins degrees of… Continue reading Suppression of androgen receptor (AR) activity in prostate malignancy by androgen